ID
16079
Beschrijving
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00022971
Link
https://clinicaltrials.gov/show/NCT00022971
Trefwoorden
Versies (1)
- 28-06-16 28-06-16 -
Geüploaded op
28 juni 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Diffuse Large B-cell Lymphoma NCT00022971
Eligibility Diffuse Large B-cell Lymphoma NCT00022971
- StudyEvent: Eligibility
Beschrijving
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Beschrijving
pregnant or nursing, willing to use contraception
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0032961
- UMLS CUI [1,2]
- C0006147
- UMLS CUI [1,3]
- C0700589
Beschrijving
prior apolizumab treatment
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1514463
- UMLS CUI [1,2]
- C1122758
Beschrijving
cardiac, cerebrovascular or peripheral vascular disease
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C0007222
- UMLS CUI [1,2]
- C0007820
- UMLS CUI [1,3]
- C3841707
Beschrijving
active cns lymphoma
Datatype
boolean
Alias
- UMLS CUI [1]
- C0742472
Beschrijving
chemotherapy or systemic steroid therapy
Datatype
boolean
Alias
- UMLS CUI [1]
- C0392920
- UMLS CUI [2]
- C0149783
Similar models
Eligibility Diffuse Large B-cell Lymphoma NCT00022971
- StudyEvent: Eligibility
C0024419 (UMLS CUI [2])
C0348026 (UMLS CUI [2,1])
C1513882 (UMLS CUI [2,2])
C1515119 (UMLS CUI [1,2])
C1514463 (UMLS CUI [2,1])
C4047978 (UMLS CUI [2,2])
C0005821 (UMLS CUI [2])
C0201976 (UMLS CUI [3])
C0373595 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C1278039 (UMLS CUI [6])
C0006147 (UMLS CUI [1,2])
C0700589 (UMLS CUI [1,3])
C1122758 (UMLS CUI [1,2])
C0007820 (UMLS CUI [1,2])
C3841707 (UMLS CUI [1,3])
C0149783 (UMLS CUI [2])
Geen commentaren